(ABI) Applied Biosystems and Sciex announced plans to commercialize a first-of-its-kind mass spectrometry platform designed to help pharmaceutical companies accelerate the drug compound screening process.
(AMTD) Ameritrade $0.23 EPS vs $0.24e.
(BDK) Black & Decker raised guidance.
(CEGE) Cell Genesys up 7% after positive drug data presented.
(CMA) Comerica $1.19 EPS vs $1.18e.
(CPLA) Capella’s is delaying its planned offering.
(DJ) Dow Jones $0.27 EPS ($0.25 after $0.02 tax benefit) vs $0.19e.
(ETR) Entergy guides EPS lower to $1.01 EPS vs $1.06e.
(GTXI) GTX reported that its Ostarine improved insulin resistance among elderly patients in a recently completed Phase II clinical trial.
(IBM) IBM reports earnings after the close; $1.21 est.
(IFIN) Investors Financial $0.60 EPS vs $0.53e.
(INTC) Intel reports after the close; $0.22 est.
(JNJ) J&J $1.16 EPS vs $1.05 estimates; Revenues $15.0 Billion versus $14.45 B est.
(JOSB) Jos A. Bank $1.36 EPS vs $1.25e.
(KEY) KeyCorp $0.89 EPS vs $0.71e.
(KO) Coca-Cola $0.56 EPS vs $0.53e.
(MEL) Mellon Financial $0.61 EPS vs $0.58e.
(RF) Regions Financial $0.69 EPS vs $0.67e.
(RMBS) Rambus signed joint-marketing agreement with TES Electronic Solutions mostly for European markets.
(STI) SunTrust $1.44 EPS vs $1.41e.
(STT) State Street $0.93 EPS vs $0.91e.
(TELK) Telik reports positive data demonstrating synergy in combination and highly statistically significant effect of Telcyta.
(UNH) United Health broadened and extended its AARP pact.
(VG) Vonage may be in talks to sell itself to Sprint according to Lightreading.com.
(WFC) Wells Fargo $0.66 EPS vs $0.65 est.
(YHOO) Yahoo! reports earnings after the close; $0.11 est.
Jon C. Ogg
April 17, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
